The US Food and Drug Administration (FDA) has launched the Global Reliance Disclosure Programme (GRDP), an initiative that will allow foreign regulatory authorities to access the agency’s scientific and regulatory assessments of approved drugs and biologics through participating applicants. The programme is intended to support regulatory reliance, reduce duplication of reviews and potentially accelerate patient access to medicines across countries.
Under the GRDP, the FDA will share minimally redacted approval packages, including detailed scientific and regulatory assessments, with applicants. Companies can then submit these documents to regulatory authorities outside the US to support their marketing applications. The programme allows foreign authorities to use the FDA’s review findings while retaining independent decision-making authority over their own regulatory approvals.
The programme was launched on October 30, 2026, initially covering tentative approvals under the President’s Emergency Plan for AIDS Relief (PEPFAR), excluding tentatively approved abbreviated new drug application products. Its first application involved lenacapavir, a drug indicated for HIV prevention and treatment.
The FDA plans to expand the programme in January 2027 to cover all novel drugs and biologics, including New Molecular Entity New Drug Applications and 351(a) Biologics License Applications. The agency also intends to introduce a separate pathway in early 2027 to facilitate requests for minimally redacted approval packages for drugs and biologics that have already received FDA approval or licensure.
Applicants seeking to participate in the GRDP must submit their request within 10 calendar days of approval and confirm that the approval package will be submitted to a foreign regulatory authority in support of a marketing application. Eligible applicants will receive further instructions through FDA approval letters, with the agency intending to provide the documents on an expedited basis. Requests for approval packages for other purposes will continue to be handled through the Freedom of Information Act (FOIA) process.
According to the FDA, the programme is intended to address delays in medicine availability across countries, particularly in regions where regulatory authorities have limited resources and may require months or years to complete independent reviews after a medicine receives approval in the US.
The agency stated that sharing regulatory assessments could support greater alignment in product evaluations, reduce duplicated regulatory work and help improve access to medicines in lower-resource settings. The programme is also intended to support global health security by encouraging more consistent regulatory standards across markets.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy